Latest Pompe Disease Pipeline Review, H2 2016, provides in depth analysis on Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) targeted pipeline therapeutics.
Pompe Disease therapeutics industry report provides comprehensive information on the therapeutics under development for Pompe Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pompe Disease and features dormant and discontinued projects.
Browse more detail information about Pompe Disease market report at: http://www.absolutereports.com/pompe-disease-pipeline-review-h2-2016-10405237
Pompe disease is an inherited disorder caused by defect in a gene called GAA. The GAA gene is responsible for the production of the GAA enzyme (acid alpha-glucosidase). This enzyme is needed to break down glycogen, a form of sugar stored in muscle cells. When too much glycogen builds up in the muscle cells, the cells become damaged and the muscles cannot function properly. Symptoms include respiratory failure, muscle pain, proximal muscle weakness, respiratory tract infections, headache and difficulty chewing or jaw muscle fatigue.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Key players in Pompe Disease – Pipeline Review, H2 2016:
- Alexion Pharmaceuticals Inc
- Amicus Therapeutics, Inc.
- Audentes Therapeutics, Inc.
- EpiVax, Inc.
- Etubics Corporation
- Genzyme Corporation
- greenovation Biotech GmbH
- Oxyrane Belgium NV
- Pharming Group N.V.
- RespireRx Pharmaceuticals Inc.
- Sarepta Therapeutics, Inc.
Get a PDF Sample of Pompe DiseaseMarket Research Report at: http://www.absolutereports.com/enquiry/request-sample/10405237
Drug Profiles of Included in Pompe Disease Therapeutics Development Market Report
- Antisense Oligonucleotide to Activate Lysosomal Alpha-Glucosidase for Pompe Disease
- ATB-200 + miglustat
- Gene Therapy 2 to Activate Acid Alpha-Glucosidase for Pompe Disease
And other drug profiles
Have any query? ask our expert @ http://www.absolutereports.com/enquiry/pre-order-enquiry/10405237
Key Topics Covered:
2.Pompe Disease Overview
3.Pompe Disease Therapeutics Development
4.Pipeline Products for Pompe Disease – Overview
5.Pipeline Products for Pompe Disease – Comparative Analysis
6.Pompe Disease – Therapeutics under Development by Companies
7.Pompe Disease – Therapeutics under Investigation by Universities/Institutes
8.Pompe Disease Products Glance
9.Late Stage Products
10.Clinical Stage Products
11.Early Stage Products
12.Pompe Disease – Products under Development by Companies
13.Pompe Disease – Products under Investigation by Universities/Institutes
14.Pompe Disease – Companies Involved in Therapeutics Development
15.Pompe Disease Drug Profiles
16.Pompe Disease Dormant Projects
17.Pompe Disease Discontinued Products
18.Pompe Disease Featured News & Press Releases
Get Discount on Pompe Disease Market Research Report at: http://www.absolutereports.com/enquiry/request-discount/10405237
This research study help to:
– Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
– Identify and understand important and diverse types of therapeutics under development for Pompe Disease
– Identify potential new clients or partners in the target demographic
– Develop strategic initiatives by understanding the focus areas of leading companies
– Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
– Devise corrective measures for pipeline projects by understanding Pompe Disease pipeline depth and focus of Indication therapeutics
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
– Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
About Absolute Report:
Absolute Reports is an upscale platform to help key personnel in the business world in strategizing and taking visionary decisions based on facts and figures derived from in depth market research. We are one of the top report resellers in the market, dedicated towards bringing you an ingenious concoction of data parameters.
Mr. Ameya Pingaley
+1-408 520 9750
Email – email@example.com